ACME Laboratories (DHA:ACMELAB) Total Stockholders Equity: BDT27,989 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
85 GF Score
Price BDT77.90
GF Value BDT128.51
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is ACME Laboratories Total Stockholders Equity?

ACME Laboratories DHA:ACMELAB 85 Total Stockholders Equity is BDT27,989 Mil as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT128.51 (Possible Value Trap). The stock has 7 warning signs investors should review.

ACME Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2026 was BDT27,989 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. ACME Laboratories's Book Value per Share for the quarter that ended in Mar. 2026 was BDT132.27. The ratio of a company's debt over equity can be used to measure how leveraged this company is. ACME Laboratories's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.85.

ACME Laboratories  (DHA:ACMELAB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

ACME Laboratories's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(27989.267-0)/211.602
=132.27

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

ACME Laboratories's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(16656.442 + 7099.997) / 27989.267
=0.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories Total Stockholders Equity Related Terms

ACME Laboratories Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories Total Stockholders Equity Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 19,044.18 20,110.60 21,690.12 23,295.12 25,051.83

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25,470.68 26,065.76 27,377.23 27,290.16 27,989.27
DHA:ACMELAB
85GF Score
ACME Laboratories Ltd DHA:ACMELAB
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of BDT27,989 Mil mean?
ACME Laboratories (DHA:ACMELAB) has a Total Stockholders Equity of BDT27,989 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for ACME Laboratories and its competitors.
Is ACME Laboratories' Total Stockholders Equity too high?
ACME Laboratories' current Total Stockholders Equity is BDT27,989 Mil. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Total Stockholders Equity compare to ZTS and UTHR?
ACME Laboratories' Total Stockholders Equity of BDT27,989 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for ACME Laboratories and its competitors. ACME Laboratories's current Total Stockholders Equity is BDT27,989 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT128.51, compared to a current price of BDT77.90 — trading 39.4% below its estimated fair value. The current Total Stockholders Equity is BDT27,989 Mil. ACME Laboratories' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Total Stockholders Equity is BDT27,989 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT77.90 is trading 39.4% below its estimated GF Value™ of BDT128.51. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • Total Stockholders Equity: BDT27,989 Mil
  • GF Value™: BDT128.51 vs. price of BDT77.90 (39.4% below fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score

Get the complete analysis for DHA:ACMELAB

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT77.90
Price
BDT128.51
GF Value